Diego A. Díaz-García, Medical Oncologist /CEO/Founder at CánCare – High Specialty in Oncology and Medical Oncologist at Angeles del Carmen Hospital, shared a post on X:
“MTAP deletions in NSCLC and EGFR.
MTAP del in 10% (n=4926). In stage IV, 83% co-occurred with drivers; EGFR in 48%.
Shorter time to osimertinib discontinuation (19.0 vs 24.9 mo; HR 1.8; p=0.01). No significant OS difference.
Acquired MTAP del at resistance in 13%. Signal of activity with PRMT5 inhibition (BMS-986504).”
Title: Clinical Significance of MTAP Deletions and Their Overlap With Concurrent Oncogenic Driver Alterations Including EGFR in NSCLC
Authors: Jessica S. Ross, Rohit Thummalapalli, Christopher A. Febres-Aldana, Daniel Muldoon, Christina Falcon, Amanda Pupo, Noura J. Choudhury, Guillherme Harada, Soo-Ryum Yang, Scott Eckert, Francis M. Bodd, Jennifer L. Sauter, Chaitanya Bandlamudi, Michael Berger, Mark Y. Jeng, Michael Offin, Alexander Drilon, Mark G. Kris, Mark M. Awad, Helena Yu, Gregory J. Riely, Marc Ladanyi, Kathryn C. Arbour
Read the Full Article.
KRAS G12C Inhibitors In NSCLC: From “Undruggable” To First-Line Contender
